An update from Benitec Biopharma (BNTC) is now available.
On August 29, 2024, a virtual Special Meeting saw participation from 58.97% of shareholders, where two key proposals were passed. The first proposal, referred to as the Nasdaq Proposal, received overwhelming support with minimal opposition and abstentions. Similarly, the second proposal for the amendment to the 2020 Equity and Incentive Compensation Plan was approved, albeit with a more significant number of votes against and abstentions. Due to the approval of these proposals, the planned adjournment was unnecessary and thus not presented.
Find detailed analytics on BNTC stock on TipRanks’ Stock Analysis page.
